A new study in
@JAMAOnc, led by
@LovaSunMD &
@CharuAggarwalMD, suggests that a 2-year immunotherapy duration is reasonable for advanced
#lungcancer, and indefinite immunotherapy is not associated with improved survival.
#NSCLC #ASCO23 t.co/sYzlhR39to